This study checks the safety of a new medicine called TTI-101 for people with a lung disease called idiopathic pulmonary fibrosis (IPF). IPF is a condition where the lungs become scarred, and it gets harder to breathe over time. Participants will take TTI-101 by mouth every day for 12 weeks. In this study, doctors will watch to see if the medicine is safe and how people feel taking it.

• The study lasts for 12 weeks.
• Participants must not have any serious infections or other lung diseases recently.
• You can't join if you have had certain treatments like pirfenidone or if you smoke.

To join, you must have been diagnosed with IPF in the last 7 years and pass some lung tests. You should not expect to have a lung transplant during the study. This study might not be right for you if you are on high doses of steroids or have other serious health problems. It's important to think about the length of the study and whether you meet the health criteria before deciding to join.